CATX

#3175
Perspective Therapeutics, Inc. Common Stock
3.0 8 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.06
3.08
Intervallo Annuale
1.96
6.16
Variazione giornaliera
-1.28%
Variazione Mensile
+5.84%
Variazione di 6 mesi
-38.65%
Variazione Annuale
-7.23%
Chiusura Precedente
3.1 2
Open
3.0 8
Minimo
3.0 6
Massimo
3.0 8
Volume
101
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Perspective Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K

Perspective Therapeutics, Inc. current report, Q3 FY2026

Full document

Perspective Therapeutics, Inc. (CATX) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Perspective Therapeutics, Inc. on August 10, 2026. The filing primarily serves to announce the Company's financial results for the quarter ended June 30, 2026, and to provide recent business highlights. The Company is incorporated in Delaware and trades on the NYSE American LLC under the symbol CATX.

Key Financial Metrics

The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The 8-K explicitly states that the detailed financial results are contained within a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this summary.

Material Changes

No specific material changes versus the prior comparable period are detailed in the text of this filing. The document indicates that such information is available in the referenced press release (Exhibit 99.1).

Guidance, Outlook, and Other Events

  • Business Highlights: The Company issued a press release on August 10, 2026, containing business highlights alongside the Q2 2026 financial results.
  • Corporate Presentation: Under Item 8.01, the Company posted an updated corporate presentation to its website, filed as Exhibit 99.2.
  • Legal Disclaimer: The information furnished in this Item 2.02 and the associated exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash position figures.
  • Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines, pipeline status, and forward-looking guidance.
  • Verify the Company's cash runway and burn rate as disclosed in the full press release to assess liquidity risks.
  • Confirm any new regulatory milestones or partnership announcements mentioned in the business highlights.

Notizie